MPN

I was shocked when I was diagnosed with a myeloproliferative neoplasm, and have dedicated myself to learning about the disease since.

Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera.

Watch Dr. Aaron Gerds and Dr. Andrew Kuykendall answer questions about myelofibrosis during the CURE Educated Patient MPN Summit.

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms.

Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Watch Dr. Jamile Shammo and Dr. John Mascarenhas answer questions about polycythemia vera during the CURE Educated Patient MPN Summit.

Research efforts will improve the lives of patients with myelofibrosis, though those advancements may take years to come, an expert said.

Watch Dr. John Mascarenhas, from the Icahn School of Medicine at Mount Sinai, discuss future treatments for polycythemia vera, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile M. Shammo, from Northwestern University Feinberg School of Medicine, discuss current treatment options in polycythemia vera during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron Gerds and Dr. Douglas Tremblay answer questions about essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Douglas A. Tremblay, from Mount Sinai, discuss treatment for essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron T. Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss essential thrombocythemia risk during the CURE Educated Patient MPN Summit.

Patients with myelofibrosis should be open about their treatment goals with their providers, and potentially consider getting a second opinion or participating in a clinical trial, one expert says.

Treatment with the novel drug GB2064 was associated with decreased fibrosis in patients with myelofibrosis, a type of blood cancer, according to findings from an ongoing phase 2 trial.

A decision to rename myeloproliferative neoplasms led to a plethora of developments in a space where there was once little interest.

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement.

Treatment with Ayvakit was associated with promising outcomes in patients with mastocytosis, according to findings from the PIONEER trial.

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

Sierra Oncology noted in a company-issued press release that if momelotinib is approved by the FDA that they anticipate making the drug available to patients with myelofibrosis next year.

It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.

From Tampa Bay Buccaneers quarterback Tom Brady letting children with cancer dye his hair orange to the name of a cancer drug causing controversy at the Scripps National Spelling Bee, here’s what’s happening in the cancer space this week.

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

Myelofibrosis may cause major impairments to a patient’s quality of life, which is why it is pertinent that patients work with their clinicians to address these side effects.

Watch Dr. Jamile Shammo and Dr. Srdan Vestovsek answer questions about disease approaches during the CURE Educated Patient MPN Summit.

Watch Dr. Srdan Vestovsek, from The University of Texas MD Anderson Cancer Center, discuss novel agents and clinical trials in myelofibrosis, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, from Rush University Medical Center, discuss differentiating an essential thrombocythemia diagnosis, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, Dr. Angela Fleishman and Kapila Viges answer questions about clinical trials during the CURE Educated Patient MPN Summit.